Spinal cord injury and use of botulinum toxin in reducing spasticity

Physical Medicine and Rehabilitation Clinics of North America

Volumn 14, Issue 4, 2003, Pages 901-910

  Fried, Guy W ^a   Fried, Karen Mandzak ^b  

^a Magee Rehabilitation Hospital   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; DANTROLENE; DIAZEPAM; GABAPENTIN; TIZANIDINE;

CONFUSION; DEPRESSION; DROWSINESS; DRUG EFFICACY; FATIGUE; HALLUCINATION; HEPATITIS; HUMAN; HYPOTENSION; INTELLECTUAL IMPAIRMENT; MENTAL DEFICIENCY; NAUSEA; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SPASTICITY; SPINAL CORD INJURY; VERTIGO;

EID: 0141919693     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1047-9651(03)00097-4     Document Type: Review

References (31)

1. Go BK, Devivo MJ, Richard JS. The epidemiology of spinal cord injury. In: Stover SL, Delisa JA, Whiteneck GG, editors. Spinal cord injury: clinical outcomes from the model systems. Gaithersburg (MD): Aspen; 1995. p. 21-55.
2. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Doella WP, editors. Spasticity: disordered motor control. Chicago: Yearbook Medical Publishers; 1980. p. 485-94.
3. Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve 1997;(Suppl 6):1-14.
4. Maynard FM, Karunas RS, Waring WP. Epidemiology of spasticity following traumatic spinal cord injury. Arch Phys Med Rehabil 1990;71:566-9.
5. Little JW, Micklesen P, Umlauf R, Britell C. Lower extremity manifestations of spasticity in chronic spinal cord injury. Am J Phys Med Rehabil 1989;68:32-6.
6. Eyzabuirre C, Fidone SJ. Physiology of the nervous system. 2nd edition. Chicago: Year book Medical Publishers; 1975. p. 210-38.
7. Young RR. The physiology of spasticity and its response to therapy. Ann N Y Acad Sci 1988;531:146-9.
8. Landau WM. Spasticity. What is it? What is it not? In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book Publishers; 1980. p. 17-24.
9. Kirshblum S. Treatment alternatives for spinal cord injury related spasticity. J Spinal Cord Med 1999;22:199-215.
10. Umbach I, Heilporn A. Post-spinal cord injury syringomelia. Paraplegia 1991;29:219-21.
11. Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol 1985;17:107-16.
12. Guissard N, Dvchateur J, Hainant K. Muscle stretching and motoneuron excitability. Eur J Appl Physiol 1988;58:47-52.
13. McPherson JJ, Becker AH, Franszczak N. Dynamic splint to reduce the passive component of hypertonicity. Arch Phys Med Rehabil 1985;66:249-52.
14. Ditunno JF, Formal CS. Chronic spinal cord injury. N Engl J Med 1994;220:550-6.
15. Merritt JL. Management of spasticity in spinal cord injury. Mayo Clin Proc 1981;56: 614-22.
16. Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 1994;44(Suppl 9):60-9.
17. Wagstaff AJ, Bryson HM. Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997;52:435-57.
18. Penn RD. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg 1992;77:236-40.
19. Meythalar JM, McCary A, Hadley MN. Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. J Neurosurg 1997;87:415.
20. Zafonte RD, Munin MC. Phenol and alcohol blocks for treatment of spasticity. Phys Med Rehabil Clin N Am 2001;12:817-32.
21. Callaway JE, Grethlein AJ. Production quality, and stability of botulinum toxin B (Myobloc) for clinical use. In: Brin MF, Hallet M, Jankovic J, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 115-23.
22. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, et al. Safety and efficacy of neurobloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-8.
23. Yablon SA. Botulinum neurotoxin intramuscular chemodenervation. Phys Med Rehabil Clin N Am 2001;12:833-73.
24. Eleopra R, Tugnoli V, Caniatti L, DeGrandis D. Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 1996;46:1158-60.
25. Dykstra DD. Use of botulinum toxin in urologic disorders.In scientific and therapeutic aspects of botulinum toxin. In: Brin MF, Jankovic J, Hallet M, editors. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 351-9.
26. Takenaga S, Kawahigashi Y, Sonoda Y, Horikiri T, Hirata K, Arimura K, et al. Treatment of spastic paraparesis with botulinum toxin with reference to beneficial effects, disease severity and long term treatment. Rinsho Shinkeigaku 1995;35:251-5.
27. Keren O, Shinberg F, Catz A, Giladi N. Botulin toxin for spasticity in spinal cord damage by treating the motor endplate. Harefuah 2000;138:204-8.
28. Al-Khodairy AT, Gobelet C, Rossier AB. Has botulinum toxin type A a place in the treatment of spasticity in spinal cord injury patients? Spinal Cord 1998;36:854-8.
29. Richardson D, Edwards S, Sheean GL, Greenwood RJ, Thompson AJ. The effect of botulinum toxin on hand function after incomplete spinal cord injury at the level of C5/6: a case report. Clin Rehabil 1997;11:288-92.
30. Fried GW. Botulinum toxin B improves spasticity and function in patient with quadriplegia. In: Naunyn-Schmiedeberg K, editor. Archives of pharmacology. Volume 354, supplement 2. Berlin: Springer-Verlag; 2002. p. R20.
31. Fried GW. Botulinum toxin B improves pain and function in patient with spasticity due to quadriplegia. In: Naunyn-Schmiedeberg K, editor. Archives of pharmacology. Volume 354, supplement 2. Berlin: Springer-Verlag; 2002. p. R20.